Form 4: Neurocrine Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed stock options and sold shares according to a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised non-qualified stock options to acquire 272 shares of common stock on April 1, 2024, at a price of $79.02 per share.
• Simultaneously, Delaet sold 272 shares of common stock at $137.3 per share.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and holds options for 5,172 shares.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to insider trading under a pre-arranged plan, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. The use of 10b5-1 plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-defined trading plan and do not indicate a change in the company's fundamentals.

Key Dates